# Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

> **NCT04186013** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 39 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Atezolizumab Injection [Tecentriq]
- **RADIATION:** External Beam Radiation Therapy (EBRT)

## Key facts

- **NCT ID:** NCT04186013
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-18
- **Primary completion:** 2027-02
- **Final completion:** 2027-05
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2022-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04186013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04186013, "Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04186013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*